SecBot SecBot

ERAS

Erasca, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001761918 Biotech & Drug Discovery
$15.11 −0.55 (−3.51%)
Nov 16 4:00 PM ET · prev $15.66
Market cap
$5.5B
Mid cap
Median target
$22.00
+46% · range $20.00–33.00
1 year
+426.5%
from $2.87 · Nov 17
30 days
+10.9%
from $13.62
52-week range
$2.76–22.47
−33% from high · low Nov 19
Avg volume 20D
5.09M
Nov 11 spike 13.79M
Short interest
37.16M
≈10.6% of shares · +0.5%
Days to cover
8.9
at average volume
Insider net
−$1.6M
0 buyers · 2 sellers · 12 mo
New fund stakes
3
Q3 2026 13F · 1 exit
Reddit crowd
60°
Warm · 1 mention this week
Filing reports
20
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 0 bearish · 1 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 2/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $1.6M.

  • InstitutionsBULLISH

    Q3 2026: 36 added (3 new), 18 trimmed or exited. Largest new: Qube Research & Technologies $18.4M.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.126 → −$0.152 over 90 days. 4 up, 4 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.5% to 37.16M shares. 8.9 days to cover, ≈10.6% of shares.

  • TrendUPTREND

    1% above its 50-day average.

  • SocialQUIET

    Crowd 60° (warm) this week from 1 mention: 1 bullish, 0 bearish. No setup is alerting.

Who's buying

13F· Q3 2026
3
new positions
1
exit
$18.4M
in new stakes · top 1 shown
FundMoveSharesValue
Capital World InvestorsDOUBLED9,361,401$137.2M
VANGUARD PORTFOLIO MANAGEMENT LLCDOUBLED8,450,131$123.9M
Assenagon Asset Management S.A.DOUBLED4,128,332$60.5M
UBS Group AGADD2,734,587$40.1M
FEDERATED HERMES, INC.ADD1,570,517$23.0M
Qube Research & Technologies LtdNEW1,253,876$18.4M
JPMORGAN CHASE & CODOUBLED1,121,849$16.1M
Rafferty Asset Management, LLCADD362,347$5.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

Last action Aug 2026
12-month targets · 9 analysts

Price is below the lowest target. Median implies +46%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Aug 14, 2026B of A Securities
MAINTAIN
MAINTAINNeutral
Aug 13, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Aug 12, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jul 20, 2026Morgan Stanley
MAINTAIN
MAINTAINEqual-Weight
Jul 14, 2026B of A Securities
MAINTAIN
MAINTAINNeutral
Jun 4, 2026B of A Securities
UPGRADE
UPGRADENeutral

Insider ledger

Form 4
$0
bought · 0 insiders
$1.6M
sold · 2 insiders
DateInsiderTypeValue
Aug 10, 2026
Fuchs Charles S.
President, R&D
Aug 10, 2026
AWARD1,300,000 sh
Jun 26, 2026
Hambleton Julie
Director
Jun 26, 2026
AWARD29,888 sh
Jun 26, 2026
LIU JEAN I
Director
Jun 26, 2026
AWARD29,888 sh
Jun 26, 2026
Bristol James Arthur
Director
Jun 26, 2026
AWARD29,888 sh
Jun 26, 2026
Casdin Alexander W.
Director
Jun 26, 2026
AWARD29,888 sh
Jun 26, 2026
Multani Pratik S
Director
Jun 26, 2026
AWARD29,888 sh
Jun 26, 2026
Start Valerie Denise Harding
Director
Jun 26, 2026
AWARD29,888 sh
Apr 1, 2026
Garner Ebun
Chief Legal Officer
Apr 1, 2026
EXERCISE$136.0K

Earnings setup

Estimates
−$0.15
EPS estimate, this quarter
−21%
estimate change, 90 days
4↑ 4↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.15-$0.19–-$0.12-15.1%$0.00
Next Q-$0.14-$0.17–-$0.08-9.1%$0.00
Current FY-$1.02-$1.05–-$0.99-4.5%$0.00
Next FY-$0.75-$1.15–-$0.47-20.1%$0.00
Reddit
Crowd this week 60° Warm 1 bullish · 0 bearish
Mentions, 7 days 1 0 in posts · 1 in comments
Recent comments
All social signals and their track records

Short side

FINRA· Oct 30, 2026
37,156,627
shares short
+0.5%
vs prior settlement
8.9
days to cover
≈10.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Other
🔒 Fresh data, subscribers only
Sep 30, 2026 Inst.
Capital World Investors · DOUBLED
9,361,401 shares ($137.2M)
Sep 30, 2026 Inst.
VANGUARD PORTFOLIO MANAGEMENT LLC · DOUBLED
8,450,131 shares ($123.9M)
Aug 10, 2026 Insider
Fuchs Charles S. was granted 1,300,000 shares
President, R&D
Jul 13, 2026 Press
Erasca has priced an upsized public offering of 31,428,572 shares at $17.50/share, expecting ~$550M in gross proceeds…
Impact 7/10
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 16, 2026
Press release
🔒 Fresh data, subscribers only
Nov 12, 2026
Earnings
Erasca Reports Third Quarter 2026 Business Updates and Financial Results
ERAS-0015 granted FDA Fast Track Designation for metastatic pancreatic adenocarcinoma; advancing toward three potentially registration-enabling…
Nov 12, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
NEW YORK, Nov. 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company")…
Nov 11, 2026
Earnings date
ERAS Q3 2026 Earnings After Market Close · 2026-11-11
Nov 5, 2026
Press release
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
NEW YORK, Nov. 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Erasca, Inc. ("Erasca" or the "Company")…

SecBot reports

20 filings · 6 press releases · 5 bullish · 0 bearish · 4 mixed · 11 neutral
All ERAS filing & press-release reports (26)